Lemna Bio awarded a CHF 100’000 EPFL Innogrant

Lemna Bio – an EPFL startup hosted by Professor Dal Pararo’s Laboratory of Biomolecular Modeling – has been awarded a CHF 100,000 Innogrant by the jury at the EPFL Startup Launchpad.

With ageing populations and chronic diseases on the rise, the demand for effective medicines and therapies has never been greater. Yet, for decades, drug development has relied on a costly and time-consuming trial-and-error approach. Developing a single drug takes over 10 years, costs upwards of $2 billion, and faces a staggering 90% failure rate.

Lemna Bio believes that AI with a deeper understanding of the molecular world can drive a golden age of biomedicine. At the heart of their platform lies the geometric transformer – an innovative AI technology rooted in physics-driven understanding of the molecular world. By enabling better representation of molecules, and their interactions, their technology facilitates better & faster design and development of biomolecules tailored to specific functions.

Lemna’s vision and validated models have already attracted interest from leading pharmaceutical and biotech companies. While their primary focus is advancing human health, they have also received interest for applications in agriculture, highlighting the versatility of their platform.

Lemna will leverage their Innogrant to conduct large-scale benchmarking of their technology and deepen engagement with industry stakeholders.

➡️ Source: EPFL